rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Todd Foley

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, Entrada Therapeutics; Director and 10% owner, Aktis Oncology; Director, Repare Therapeutics; 10% owner, iTeos Therapeutics; Director and 10% owner, Chiasma; Director and 10% owner, Rhythm Pharmaceuticals; 10% owner, Aratana Therapeutics; Director, Celladon.

Every Form 4 they filed

In numbers

Trades disclosed
193
Buys
7
Sells
84
Bought
$29.8M
Sold
$77.4M
Companies
11
Companies where not an officer
11
First trade
15 Jan 2010
Last trade
26 Aug 2026
Last filed
26 Aug 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
TRDA Entrada TherapeuticsDirector, 10% owner · Biotechnology · last 26 Aug 20261 buy · 3 sells
AKTS Aktis OncologyDirector, 10% owner · Biotechnology · last 12 Jan 20261 buy · 0 sells
Repare TherapeuticsDirector · last 8 Jun 20231 buy · 30 sells
iTeos Therapeutics10% owner · last 11 Oct 20210 buys · 6 sells
ChiasmaDirector, 10% owner · last 5 Aug 20210 buys · 0 sells
RYTM Rhythm PharmaceuticalsDirector, 10% owner · Biotechnology · last 15 Mar 20212 buys · 44 sells
Aratana Therapeutics10% owner · last 7 Mar 20140 buys · 1 sell
CelladonDirector · last 4 Feb 20141 buy · 0 sells
Conatus Pharmaceuticals10% owner · last 30 Jul 20131 buy · 0 sells
Radius Health10% owner · last 23 Apr 20130 buys · 0 sells
ZalicusDirector · last 23 May 20120 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
301Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
26 Aug 2026filed 26 Aug 2026TRDA Entrada TherapeuticsBiotechnologySEC FORM 4 Sold$103K14,569 at $7.06filing
25 Aug 2026filed 26 Aug 2026TRDA Entrada TherapeuticsBiotechnologySEC FORM 4 Sold$200K26,522 at $7.54filing
24 Aug 2026filed 26 Aug 2026TRDA Entrada TherapeuticsBiotechnologySEC FORM 4 Sold$159K21,623 at $7.34filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—597,391filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—2,688,270filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—716,872filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—2,272,727 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—10,227,273 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—2,727,273 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Bought$4.2M232,870 at $18.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—2,272,727 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—10,227,273 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—2,727,273 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—597,391filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—2,688,270filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—716,872filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Bought$4.2M232,870 at $18.00filing
8 Jun 2023filed 12 Jun 2023Repare Therapeuticsoption or derivativeSEC FORM 4 Code A—27,200 at $0.00filing
2 Jun 2022filed 6 Jun 2022TRDA Entrada Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—11,918 at $0.00filing
13 May 2022filed 16 May 2022Repare Therapeuticsoption or derivativeSEC FORM 4 Code A—49,000 at $0.00filing

News

PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastAKTS · dailypolitical.com · 19 Oct 2026Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45TRDA · manilatimes.net · 14 Oct 2026Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyTRDA · manilatimes.net · 14 Oct 2026Comparing Black Diamond Therapeutics (NASDAQ:BDTX) & Entrada Therapeutics (NASDAQ:TRDA)TRDA · themarketsdaily.com · 11 Oct 2026Reviewing Aktis Oncology (NASDAQ:AKTS) and Oncocyte (NASDAQ:IMDX)AKTS · tickerreport.com · 7 Oct 2026Critical Survey: Aktis Oncology (NASDAQ:AKTS) vs. Bicycle Therapeutics (NASDAQ:BCYC)AKTS · dailypolitical.com · 7 Oct 2026

0 headlines in the last 90 days name Todd Foley; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.

Sectors

Health Care51
Not placed40

Buys in green, sells in red, by the company’s sector.

Related people

Akos CzibereChief Medical Officer · Chief Medical Officer at Aktis Oncology, filing Form 4 there in the last year
MPM BIOVENTURES 2018, L.P.10% owner · 10% owner at Entrada Therapeutics, filing Form 4 there in the last year
MPM BioVentures 2014, L.P.10% owner · 10% owner at Entrada Therapeutics, filing Form 4 there in the last year
Dipal DoshiCEO · CEO at Entrada Therapeutics, filing Form 4 there in the last year
Natarajan SethuramanPresident, Research & Develop. · President, Research & Develop. at Entrada Therapeutics, filing Form 4 there in the last year
David P. MeekerPresident and CEO · Also traded RYTM in the last 90 days
Hunter C. SmithChief Financial Officer · Also traded RYTM in the last 90 days
Alastair GarfieldChief Scientific Officer · Also traded RYTM in the last 90 days